
Hepatorenal syndrome (HRS) represents an acute complication of decompensated cirrhosis and is a subtype of acute kidney injury (AKI), with high associated mortality. This activity consists of 6 paired conversations with experts from Europe and the United States in the fields of hepatology, critical care, nephrology, and transplantation. During these paired conversations, the faculty explore revised diagnostic criteria, emerging treatment, and coordinating effective multidisciplinary care. In addition, the faculty panel collaboratively reviews a patient case where they share international perspectives on the nonpharmacological and pharmacological treatment of patients with HRS-AKI.
This program is also available as a podcast. You may download it here: https://anchor.fm/hrs-aki
Course Credit:
1.75 ACPE Contact Hours
1.75 AMA PRA Category 1 CreditsTM
1.75 ANCC Contact Hours
Dates:
Opens: 2022-08-15
Closes: 2023-08-15
Target Audience:
This activity is intended for a national audience of critical care physicians, hepatologists, nephrologists, transplant surgeons, critical care pharmacists, nurse practitioners, physician assistants, and other clinicians who care for patients with hepatorenal syndrome-acute kidney injury (HRS-AKI).
This activity is supported by an educational grant from Mallinckrodt.
Accreditation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1.75 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.75 contact hours.
Additional Content Planners
Ishaq Lat, PharmD (Medical Writer)No significant relationships to disclose.
Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Paolo Angeli, MD, PhD
Unit of Hepatic Emergencies and Liver Transplantation
University of Padova
Padova, Italy -
Amanda Chaney, DNP, APRN
Senior Director of Advanced Practice Services
Cleveland Clinic
Florida Region
Weston, Florida -
Kevin Moore, MB.BS, PhD
Institute of Liver and Digestive Health
University College
London, United Kingdom -
Mitra K. Nadim, MD
Director, USC Hypertension Center
Keck Medicine of USC
Los Angeles, California -
Rahul Nanchal, MD
Division of Pulmonary and Critical Care Medicine
Medical College of Wisconsin
Milwaukee, Wisconsin -
Ram Subramanian, MD, MBA
Director of Liver Critical Care Services
Emory University School of Medicine
Atlanta, Georgia
Presenting Faculty
Downloads
Learning Objectives
- Implement American Association for the Study of Liver Disease (AASLD) criteria in the diagnosis of patients with HRS-AKI
- Discuss the role of nonpharmacologic and pharmacologic therapies for the treatment of HRS-AKI according to current AASLD and Society of Critical Care Medicine (SCCM) guideline recommendations
- Compare the clinical pharmacology of currently available and emerging vasoconstrictors for HRS-AKI
- Describe the safety and efficacy of vasoconstrictor options for the treatment of patients with HRS-AKI, based on clinical trials and real-world, international experience
- Compare treatment approaches to HRS-AKI recommended in AASLD and SCCM guidelines
- Apply current guideline recommendations as a multidisciplinary care team in treating patients with HRS-AKI
Faculty Disclosures
Paolo Angeli, MD, PhD
Advisory Board: BioVie, Gilead, Ferring
Research Support: Gilead
Speakers Bureau: CSL Behring, Grifols, Kedrion
Amanda Chaney, DNP, APRN
Author: Springer Publishing
Kevin Moore, MB.BS, PhD
Consultant: Mallinckrodt Pharmaceuticals
Mitra K. Nadim, MD
Consultant: Mallinckrodt Pharmaceuticals
Rahul Nanchal, MD
No relationships to disclose.Ram Subramanian, MD, MBA
Consultant: Mallinckrodt Pharmaceuticals